Format

Send to

Choose Destination
South Asian J Cancer. 2014 Jan;3(1):66-70. doi: 10.4103/2278-330X.126531.

Management of relapsed-refractory diffuse large B cell lymphoma.

Author information

1
Institute of Haematology and Transfusion Medicine, Medical College and Hospital, Kolkata, West Bengal, India.

Abstract

Relapsed-Refractory Diffuse Large B Cell Lymphoma (RR DLBCL), which accounts for approximately one-third of patients with DLBCL, remains a major cause of morbidity and mortality. Managing RR DLBCL continues to be a challenge to the treating hemato-oncologist. Salvage high-dose chemotherapy followed by autologous stem cell transplantation is the standard of care for chemosensitive relapses in DLBCL. Various salvage regimens are available, but the quest for an optimal regimen continues. The addition of rituximab to the salvage regimen has improved the outcome of RR DLBCL. Several pertinent issues regarding the management of RR DLBCL are discussed in this short review.

KEYWORDS:

Activated B cell; autologous stem cell transplant; diffuse large B cell lymphoma; germinal center B; high dose chemotherapy; relapsed refractory

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
Loading ...
Support Center